Oncotarget

Research Papers:

MicroRNA-134 plasma levels before and after treatment with valproic acid for epilepsy patients

Xiaofeng Wang, Yifeng Luo, Shuangxi Liu, Liming Tan, Sanhu Wang and Rongyong Man _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:72748-72754. https://doi.org/10.18632/oncotarget.20292

Metrics: PDF 1568 views  |   HTML 2624 views  |   ?  


Abstract

Xiaofeng Wang1, Yifeng Luo1, Shuangxi Liu2, Liming Tan3, Sanhu Wang4 and Rongyong Man2

1Department of Neurology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, 510630 China

2Department of Neurology of the First People’s Hospital of Huaihua, affiliated to University of South China, Huaihua, Hunan 418000, China

3Department of Pharmacy of the First People’s Hospital of Huaihua, affiliated to University of South China, Huaihua, Hunan 418000, China

4Medical Research Center of the First People’s Hospital of Huaihua, affiliated to University of South China, Huaihua, Hunan 418000, China

Correspondence to:

Rongyong Man, email: [email protected]

Keywords: microRNA-134, valproic acid, epilepsy, biomarker, temporal lobe epilepsy

Received: January 10, 2017     Accepted: June 12, 2017     Published: August 16, 2017

ABSTRACT

Background: Temporal lobe epilepsy is the second most common neurological disorders characterized by recurrent spontaneous seizures. MicroRNAs play a vital role in regulating synaptic plasticity, brain development and post-transcriptional expression of proteins. In both animal models of epilepsy and human patients, miR-134, a brain-specific microRNA has recently been identified as a potential regulator of epileptogenesis.

Methods: microRNA identified as targets for the actions of valproic acid (VPA) are known to have important effects in brain function. In this study, 59 new-onset epilepsy patients and 20 controls matched by sex and age were enrolled. Patients with a score < 3 were allocated into the mild group, 3-5 into the moderate group and >5 into the severe group. The plasma miRNA-134 level was quantitatively measured using real-time PCR.

Results: Plasma miRNA-134 level in new-onset epilepsy patients was significantly up-regulated when compared with that in healthy controls, and then considerably down-regulated after oral intake of valproic acid medication. The up-regulated plasma miRNA-134 levels may be directly associated with the pathophysiology and severity of epilepsy.

Conclusion: Plasma miRNA-134 in epilepsy may be considered as a potential peripheral biomarker that responds to the incidence of epilepsy and associates with use of anti-epilepsy drugs.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20292